China Approves Subcutaneous Formulation of LEQEMBI for Early Alzheimer's Disease

China's National Medical Products Administration (NMPA) has approved the subcutaneous formulation (SC-AI) of LEQEMBI (lecanemab) as an initiation treatment for mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's dementia. This approval provides a new, more convenient once-weekly self-administered option for patients, in addition to the existing intravenous administration. The decision was based on Phase 3 data from the Clarity AD clinical trial, which showed LEQEMBI significantly slowed disease progression.